Clinical Trials
16
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2009
Completed
14
87.5%
Withdrawn
2
12.5%
No approval data available
- The Commercial Court of Lyon has approved Poxel's recovery plan and ended the judicial reorganization proceedings that began on August 5, 2025. - The recovery plan includes establishing new partnerships for Imeglimin commercialization in Asia, promoting PXL770 for ADPKD, and leveraging PXL065 for HCM. - Financial restructuring involves €5 million equity line from IRIS, €3.75 million bond borrowings from IPF, and capital increases to strengthen the company's position. - The plan enables Poxel to continue developing its metabolic disease portfolio while settling outstanding liabilities and optimizing cost structure.
- Poxel SA, a clinical-stage biopharmaceutical company developing treatments for metabolic diseases, has entered judicial reorganization proceedings following a court hearing on August 5, 2025. - The company will continue operations during a six-month observation period while exploring options including a continuation plan to maintain its drug development activities. - Poxel's pipeline includes PXL065 for MASH treatment, which met its primary endpoint in the Phase 2 DESTINY-1 trial, and PXL770 for rare metabolic disorders. - Trading of Poxel shares on Euronext Paris resumed on August 11, 2025, following the court's decision to initiate the reorganization process.
- Poxel's PXL065, a deuterium-stabilized R-enantiomer of pioglitazone, demonstrated significant benefits in preventing pathological myocardial remodeling in a mouse model of hypertrophic cardiomyopathy. - The preclinical study showed PXL065 prevented hypertrophy and fibrosis in the heart, supporting its potential as a disease-modifying treatment for both symptomatic and asymptomatic HCM patients. - Results will be presented at the European Society of Cardiology Congress on September 1st, 2025, highlighting the compound's dual mechanism targeting mitochondrial dysfunction and oxidative stress. - The findings address a significant unmet medical need in HCM, which affects approximately 1 in 500 adults and currently has limited effective treatment options.
- DelveInsight's 2025 report reveals a robust pipeline with 75+ companies developing 80+ therapies for chronic kidney disease, highlighting significant industry investment in addressing this growing health concern. - Key late-stage candidates include AstraZeneca's Baxdrostat and Novo Nordisk's Ziltivekimab, targeting different pathways in CKD progression with promising clinical results. - Multiple novel mechanisms are being explored across all development stages, including aldosterone synthase inhibition, anti-inflammatory approaches, and soluble guanylate cyclase activation, expanding potential treatment options.
- Multiple companies are developing novel therapies for Adrenoleukodystrophy (ALD), a rare genetic disorder affecting the adrenal glands and nervous system. - Key emerging therapies include ABX-002 (Autobahn Therapeutics), VK0214 (Viking Therapeutics), and SBT101 (SwanBio Therapeutics), among others, targeting various aspects of the disease. - Leriglitazone (MIN102) by Minoryx Therapeutics faced a setback with a negative CHMP opinion, but a re-examination for conditional approval is planned. - Clinical trials are exploring different routes of administration, including intravenous, subcutaneous, and oral, with diverse molecule types such as monoclonal antibodies and small molecules.
